Pharmaceuticals & Therapeutics

New data reveals a novel cancer drug shrinks brain metastases in over half of small cell lung cancer patients, offering hope where options are scarce.

Presented at AACR 2026, first-in-class antibody IMT-009 shows clinical benefit in tough cancers, potentially paving the way for a new precision therapy.

A new partnership between Wilcrest Pharma and healthcare giant Premier, Inc. aims to streamline hazardous drug compounding for thousands of U.S. hospitals.

Dr. Jennifer Shuford, a crisis-tested leader from Texas, is named CDC Deputy Director, a move experts hope will stabilize the beleaguered agency.

Biotech veteran Habib Dable, who led Acceleron to an $11.5B Merck sale, joins Tyra Biosciences' board, signaling a major push toward commercialization.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

Investors eye Darling's Q1 results on April 30 for a rebound in renewable fuel profits and continued strength in its core circular economy segments.

For over a decade, Wake Radiology has backed the Komen Race for the Cure, funding research and expanding access to life-saving breast cancer screenings.

An FDA-approved system lets surgeons see residual cancer in real-time during lumpectomies, offering new hope for avoiding the dreaded second surgery.

GC Biopharma's new data on ALYGLO's purity profile could set a new standard for IVIG therapies, impacting patient safety in a rapidly growing market.

With a massively oversubscribed €600M hybrid note offering, plant-based leader Roquette secures major funding and a huge vote of investor confidence.

Despite major cost cuts and growth in key divisions, DSS, Inc. struggles to convince Wall Street. Can a biotech spin-off finally unlock its true value?

With key advisory appointments, NeuraClick aims to overcome long-standing hurdles in peptide drug development for complex brain and metabolic disorders.

With 62 profitable quarters and a major new acquisition, BioSyent prepares to pitch its proven growth strategy to top healthcare investors in Toronto.

TEDCO's latest funding round seeds 13 university-born ventures, tackling everything from hereditary hearing loss and cancer to environmental monitoring.

A new biotech player is advancing a first-in-class cancer drug that combines two payloads to fight tumors that have become resistant to current therapies.

Facing soaring costs and armed with new laws, America's largest employers are ditching old playbooks to force transparency and value from the healthcare industry.

A company named for mining is betting big on Bali's luxury villa market. But with a tiny market cap and an unknown builder, is it a brilliant pivot or a risky gamble?

A CEO's personal battle with prostate cancer inspired a community golf tournament that is now on the verge of raising $1 million for critical research.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.